Literature DB >> 16682547

Hereditary spastic paraplegia with thin corpus callosum: reduction of the SPG11 interval and evidence for further genetic heterogeneity.

Alexander Lossos1, Giovanni Stevanin, Vardiella Meiner, Zohar Argov, Naima Bouslam, J P Newman, John M Gomori, Stephan Klebe, Israela Lerer, Nizar Elleuch, Shira Silverstein, Alexandra Durr, Oded Abramsky, Ziva Ben-Nariah, Alexis Brice.   

Abstract

BACKGROUND: Hereditary spastic paraplegia (HSP) with thin corpus callosum (TCC) is an autosomal recessive form of complicated HSP mainly characterized by slowly progressive spastic paraparesis and mental deterioration beginning in the second decade of life. The locus for HSP-TCC, designated SPG11, was mapped to chromosome 15q13-15 in some of the affected families from Japan, Europe, and North America, spanning an interval of 17.5 megabases (Mb).
OBJECTIVE: To perform a clinical and genetic study of HSP-TCC. DESIGN AND
SETTING: Case series; multi-institutional study. PATIENTS: Seven patients with HSP-TCC who belong to 3 consanguineous families of Arab origin residing in Israel.
RESULTS: The 7 patients manifested a relatively similar combination of adolescence-onset cognitive decline and spastic paraparesis with TCC on brain magnetic resonance imaging. After excluding the SPG7 locus, we tested the 3 families for linkage to the SPG11, SPG21/MAST, and ACCPN loci associated with autosomal recessive disorders with TCC. Two families showed evidence for linkage to SPG11 (Z(max) = 5.55) and reduced the candidate region to 13 Mb.
CONCLUSIONS: Our findings in HSP-TCC further confirm its worldwide distribution and genetic heterogeneity, and they significantly reduce the candidate SPG11 interval.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16682547     DOI: 10.1001/archneur.63.5.756

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  10 in total

1.  A new locus (SPG46) maps to 9p21.2-q21.12 in a Tunisian family with a complicated autosomal recessive hereditary spastic paraplegia with mental impairment and thin corpus callosum.

Authors:  Amir Boukhris; Imed Feki; Nizar Elleuch; Mohamed Imed Miladi; Anne Boland-Augé; Jérémy Truchetto; Emeline Mundwiller; Nadia Jezequel; Diana Zelenika; Chokri Mhiri; Alexis Brice; Giovanni Stevanin
Journal:  Neurogenetics       Date:  2010-07-01       Impact factor: 2.660

2.  Spastizin mutation in hereditary spastic paraplegia with thin corpus callosum.

Authors:  Sanjiban Chakrabarty; Nimish Vijayakumar; Kurupath Radhakrishnan; Kapaettu Satyamoorthy
Journal:  J Neurol       Date:  2016-08-20       Impact factor: 4.849

3.  Brain white matter involvement in hereditary spastic paraplegias: analysis with multiple diffusion tensor indices.

Authors:  G Aghakhanyan; A Martinuzzi; F Frijia; M Vavla; H Hlavata; A Baratto; N Martino; G Paparella; D Montanaro
Journal:  AJNR Am J Neuroradiol       Date:  2014-04-30       Impact factor: 3.825

4.  Spastic paraplegia with thin corpus callosum: description of 20 new families, refinement of the SPG11 locus, candidate gene analysis and evidence of genetic heterogeneity.

Authors:  Giovanni Stevanin; Giorgia Montagna; Hamid Azzedine; Enza Maria Valente; Alexandra Durr; Valentina Scarano; Naima Bouslam; Denise Cassandrini; Paola S Denora; Chiara Criscuolo; Soraya Belarbi; Antonio Orlacchio; Philippe Jonveaux; Gabriella Silvestri; Anne Marie Ouvrad Hernandez; Giuseppe De Michele; Meriem Tazir; Caterina Mariotti; Knut Brockmann; Alessandro Malandrini; Marjo S van der Knapp; Marcella Neri; Hassan Tonekaboni; Mariarosa A B Melone; Alessandra Tessa; M Teresa Dotti; Michela Tosetti; Flavia Pauri; Antonio Federico; Carlo Casali; Vitor T Cruz; José L Loureiro; Federico Zara; Sylvie Forlani; Enrico Bertini; Paula Coutinho; Alessandro Filla; Alexis Brice; Filippo M Santorelli
Journal:  Neurogenetics       Date:  2006-05-13       Impact factor: 2.660

5.  Hereditary spastic paraplegia with a thin corpus callosum.

Authors:  Sivaraman Somasundaram; Seetharam Raghavendra; Atampreet Singh; Chandrasekharan Kesavadas; Muraleedharan Nair
Journal:  Pediatr Radiol       Date:  2007-03-27

6.  SPG11: a consistent clinical phenotype in a family with homozygous spatacsin truncating mutation.

Authors:  Roberto Del Bo; Alessio Di Fonzo; Serena Ghezzi; Federica Locatelli; Giovanni Stevanin; Antonella Costa; Stefania Corti; Nereo Bresolin; Giacomo Pietro Comi
Journal:  Neurogenetics       Date:  2007-08-24       Impact factor: 2.660

7.  Novel SPG11 mutations in Asian kindreds and disruption of spatacsin function in the zebrafish.

Authors:  Laura Southgate; Dimitra Dafou; Jacqueline Hoyle; Nan Li; Esther Kinning; Peter Critchley; Andrea H Németh; Kevin Talbot; Parayil S Bindu; Sanjib Sinha; Arun B Taly; Seetharam Raghavendra; Ferenc Müller; Eamonn R Maher; Richard C Trembath
Journal:  Neurogenetics       Date:  2010-10       Impact factor: 2.660

8.  Rapidly deteriorating course in Dutch hereditary spastic paraplegia type 11 patients.

Authors:  Susanne T de Bot; Rogier C Burggraaff; Johanna C Herkert; Helenius J Schelhaas; Bart Post; Adinda Diekstra; Reinout O van Vliet; Marjo S van der Knaap; Erik-Jan Kamsteeg; Hans Scheffer; Bart P van de Warrenburg; Corien C Verschuuren-Bemelmans; Hubertus P H Kremer
Journal:  Eur J Hum Genet       Date:  2013-02-27       Impact factor: 4.246

9.  Refinement of the SPG15 candidate interval and phenotypic heterogeneity in three large Arab families.

Authors:  Nizar Elleuch; Naima Bouslam; Sylvain Hanein; Alexander Lossos; Abdelmadjid Hamri; Stephan Klebe; Vardiella Meiner; Nezha Birouk; Israela Lerer; Djamel Grid; Delphine Bacq; Meriem Tazir; Diana Zelenika; Zohar Argov; Alexandra Durr; Mohamed Yahyaoui; Ali Benomar; Alexis Brice; Giovanni Stevanin
Journal:  Neurogenetics       Date:  2007-07-28       Impact factor: 3.017

10.  Clinical heterogeneity and genotype-phenotype correlations in hereditary spastic paraplegia because of Spatacsin mutations (SPG11).

Authors:  C Paisan-Ruiz; P Nath; N W Wood; A Singleton; H Houlden
Journal:  Eur J Neurol       Date:  2008-08-20       Impact factor: 6.089

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.